Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study.

MLA

Sandborn, William J., et al. “Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study.” Journal of Crohn’s & Colitis, vol. 15, no. 7, July 2021, pp. 1120–29. EBSCOhost, https://doi.org/10.1093/ecco-jcc/jjab012.

APA

Sandborn, W. J., Feagan, B. G., Hanauer, S., Vermeire, S., Ghosh, S., Liu, W. J., Petersen, A., Charles, L., Huang, V., Usiskin, K., Wolf, D. C., & D’Haens, G. (2021). Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study. Journal of Crohn’s & Colitis, 15(7), 1120–1129. https://doi.org/10.1093/ecco-jcc/jjab012

Chicago

Sandborn, William J, Brian G Feagan, Stephen Hanauer, Severine Vermeire, Subrata Ghosh, Wenzhong J Liu, AnnKatrin Petersen, et al. 2021. “Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study.” Journal of Crohn’s & Colitis 15 (7): 1120–29. doi:10.1093/ecco-jcc/jjab012.